Drugs / FDY-5301
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04430283 | Sep 2021 → Mar 2022 | myopathy | Faraday Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03470441 | Oct 2017 → Jul 2018 | ST-elevation myocardial infarction | Faraday Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04837001 | May 2022 → Sep 2025 | ST-elevation myocardial infarction | Faraday Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FDY-5301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04837001 ↗ |
| Known as | Sodium Iodide | “FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.” NCT04430283 ↗ |
| Modality | Small molecule | “FDY-5301 contains sodium iodide, a ubiquitous inorganic halide and elemental reducing agent that can act as a catalytic anti-peroxidant.” PMID 34774885 ↗ Nov 2021 |
| Route | Intravenous | “Intravenous FDY-5301 was delivered before re-opening of the infarct-related artery in 97% participants” PMID 34774885 ↗ Nov 2021 |